Company and Stock Identity

How Hologic Connects to the Public Market

Company structure
Private company owned by Blackstone and TPG
Market access
No current public listing. Hologic's shares were delisted from Nasdaq when the take-private closed on 7 April 2026.
Research focus
The quarterly numbers that used to be public stopped with the take-private, so ask for figures directly and expect less of a paper trail than before. Check which AI product any claim is about: Hologic names 510(k) numbers K201019, K221449 and K230096 for Genius AI Detection on its own site, while it says Quantra 2.2 breast density software is manufactured by Therapixel and only distributed by Hologic. Its digital cervical cytology system with an AI algorithm was granted through De Novo DEN210035 rather than cleared, and those two words carry different evidence bars.

Hologic announced on 21 October 2025 that it would be acquired by funds managed by Blackstone and TPG for 76 dollars per share in cash plus a non-tradable contingent value right worth up to 3 dollars, an enterprise value of up to 18.3 billion dollars. Its own filing says stockholders approved the deal on 5 February 2026, that the acquisition completed with the common stock ceasing to trade and being delisted from Nasdaq, and that a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC took minority stakes. The filing announcing completion was made on 7 April 2026 and says Jose E. Almeida became chief executive on completion, succeeding Stephen MacMillan.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Hologic ... Company source

Hologic says its mammography AI found most invasive lobular cancers in a hospital study

Hologic said on 20 April 2026 that a retrospective single-centre study by Massachusetts General Hospital in Boston reviewed 239 invasive lobular cancer cases diagnosed over 10 years, of which 195 were found during routine screening and 44 were read as negative at the time. The company says its Genius AI Detection solution identified and correctly localised close to 90 percent of the confirmed invasive lobular cancers, and identified 43 percent of the cases that had been read as negative during routine screening. Hologic notes that invasive lobular cancers make up roughly 10 to 15 percent of all breast cancers, and also discussed its 3DQuorum imaging technology.

Why it matters: This is the harder test for mammography AI, because invasive lobular cancer spreads in a pattern that does not form the dense lump the eye and most algorithms are tuned to find. Catching 43 percent of cases that experienced readers called negative is a meaningful result for a second-reader tool. It is also retrospective and from one hospital, which means the algorithm was shown images already known to contain cancer rather than a normal screening day, so it describes a ceiling rather than everyday performance.

... Hologic SEC filing ... Regulatory record

Blackstone and TPG finish buying Hologic, and its shares stop trading

Hologic filed on 7 April 2026 that funds managed by Blackstone and TPG had completed their acquisition of the company, with stockholders receiving 76 dollars per share in cash plus a non-tradable contingent value right of up to 3 dollars paid in two instalments of up to 1.50 dollars each if the Breast Health business hits global revenue goals in fiscal 2026 and 2027. The filing says the common stock has ceased trading and will be delisted from Nasdaq, names a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC as minority investors, and says Jose E. Almeida became chief executive on completion, succeeding Stephen MacMillan after more than 12 years. The deal was first announced on 21 October 2025 at an enterprise value of up to 18.3 billion dollars, and stockholders approved it on 5 February 2026.

Why it matters: A health system comparing imaging vendors has been using Hologic's quarterly filings to judge whether the company can keep supporting a 10-year equipment estate. Those filings are gone. The contingent value right is also worth reading: part of the price depends on the Breast Health business hitting revenue goals in fiscal 2026 and 2027, which is the same business that sells the AI software, so the owners have a reason to push sales hard in exactly that window. None of that says the products will get worse, but it does mean a buyer should put support and upgrade commitments in the contract rather than trusting a public track record.

... Hologic ... Company source

Hologic says its AI flagged a third of breast cancers first read as negative

Hologic said on 16 December 2025 that a retrospective analysis by Massachusetts General Hospital in Boston, published in the American Journal of Roentgenology, examined 7,500 digital breast tomosynthesis screening exams carried out between 2016 and 2019. The analysis found 100 false negative cases, and the company says its Genius AI Detection solution marked about one third of them, 32 percent.

Why it matters: A screening program's real cost is the cancer found a year late, so a second reader that catches a third of the misses is worth pricing even if it changes nothing on the other 7,400 exams. The study is retrospective and looks only at cases later known to be cancer, so it cannot tell you how many extra healthy women would have been called back. A program should ask for both halves of that trade before committing, because recall rate is what the staff will feel every day.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers site sorts work by region rather than by role, listing 10 North American sites with about 4,150 staff, 15 sites across Europe, the Middle East and Africa with about 1,046, six in Asia Pacific with about 540, and two in Latin America with about 824.

Qualification signal: This is a device manufacturer, not a software startup, so the AI work sits inside hardware release cycles and regulatory submissions. Candidates who have shipped software that runs on a cleared medical device have the experience that transfers; pure web or model experience does not.

Check current roles at Hologic. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Hologic appears on 6 cleared products in the federal 510(k) record, across 3 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources